Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-11-07

Clinical Trial Update: Tiotropium/Salmeterol Inhalation Powder in COPD [Phase 3]

View source ↗

Summary

Phase 3 trial update for tiotropium/salmeterol inhalation powder in chronic obstructive pulmonary disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • tiotropium/salmeterol inhalation powder

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: TERMINATED